Study on Combining Dasatinib or Imatinib with Chemotherapy and Blinatumomab for Young Patients with Specific Types of B-cell Acute Lymphoblastic Leukemia

Program Overview

This study is testing a new combination of treatments for young patients with specific types of B-cell acute lymphoblastic leukemia (B-ALL) that have certain genetic markers, known as Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like). The treatment combines standard chemotherapy with blinatumomab, a drug that helps the immune system attack cancer cells, and either dasatinib or imatinib, which are drugs that block signals that make cancer cells grow. The goal is to see if this combination works better than the current standard treatments.

Description

The main goal of this study is to see if the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy can improve the chances of staying cancer-free for three years in young patients with newly diagnosed Ph+ or ABL-class Ph-like B-ALL. The study will also look at the safety of this treatment combination and any side effects it may cause, such as infections or delays in treatment.

The study is divided into different parts, where patients will receive various treatments over time. These include cycles of chemotherapy, blinatumomab, and either dasatinib or imatinib, depending on the specific genetic markers of their leukemia. The treatment plan is designed to be as effective as possible while minimizing side effects.

Throughout the study, patients will undergo regular tests and evaluations to monitor their response to the treatment and any side effects. This includes blood tests, imaging scans, and bone marrow biopsies. The study aims to provide valuable information on whether this new treatment approach can improve outcomes for young patients with these specific types of leukemia.

Eligibility Criteria

Locations